In addition, for breast cancer patients who are resistant to the anti-HER2 monoclonal antibody trastuzumab, a novel HER2-specific exosome-T vaccine was developed using exosomes released from HER2-specific dendritic cells to target CD4+ T cells. Here, ERBB2 is linked to breast carcinoma.